Management of chronic, refractory schizophrenic patients with high-dose loxapine

L. Ereshefsky; S. R. Saklad; T. E. Mings; C. R. Lehmann

Management of chronic, refractory schizophrenic patients with high-dose loxapine

L. Ereshefsky, S. R. Saklad, T. E. Mings, C. R. Lehmann

Research output: Contribution to journal › Article › peer-review

Abstract

The authors suggest that schizophrenic patients unresponsive to other antipsychotic agents should be considered for a trial on loxapine. The loxapine dosage should be slowly titrated upward unless rapid tranquilization is indicated. Use of the liquid form of medication is recommended for initiation of routine loxapine therapy to assure compliance during titration. Loxapine has been reported to cause seizures in overdose, justifying careful screening of patients for high-dose loxapine therapy. Double-blind, placebo-controlled trials are needed to verify the superiority of loxapine over other antipsychotic agents.

Original language	English (US)
Pages (from-to)	600-603
Number of pages	4
Journal	Psychopharmacology bulletin
Volume	19
Issue number	4
State	Published - Jan 1 1983

ASJC Scopus subject areas

Psychiatry and Mental health
Pharmacology (medical)

Access to Document

Fingerprint Dive into the research topics of 'Management of chronic, refractory schizophrenic patients with high-dose loxapine'. Together they form a unique fingerprint.

Cite this

@article{b17ac2919fe544b58ca712d38be1618b,

title = "Management of chronic, refractory schizophrenic patients with high-dose loxapine",

abstract = "The authors suggest that schizophrenic patients unresponsive to other antipsychotic agents should be considered for a trial on loxapine. The loxapine dosage should be slowly titrated upward unless rapid tranquilization is indicated. Use of the liquid form of medication is recommended for initiation of routine loxapine therapy to assure compliance during titration. Loxapine has been reported to cause seizures in overdose, justifying careful screening of patients for high-dose loxapine therapy. Double-blind, placebo-controlled trials are needed to verify the superiority of loxapine over other antipsychotic agents.",

author = "L. Ereshefsky and Saklad, {S. R.} and Mings, {T. E.} and Lehmann, {C. R.}",

year = "1983",

month = jan,

day = "1",

language = "English (US)",

volume = "19",

pages = "600--603",

journal = "Psychopharmacology Bulletin",

issn = "0048-5764",

publisher = "MedWorks Media LLC",

number = "4",

}

TY - JOUR

T1 - Management of chronic, refractory schizophrenic patients with high-dose loxapine

AU - Ereshefsky, L.

AU - Saklad, S. R.

AU - Mings, T. E.

AU - Lehmann, C. R.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - The authors suggest that schizophrenic patients unresponsive to other antipsychotic agents should be considered for a trial on loxapine. The loxapine dosage should be slowly titrated upward unless rapid tranquilization is indicated. Use of the liquid form of medication is recommended for initiation of routine loxapine therapy to assure compliance during titration. Loxapine has been reported to cause seizures in overdose, justifying careful screening of patients for high-dose loxapine therapy. Double-blind, placebo-controlled trials are needed to verify the superiority of loxapine over other antipsychotic agents.

AB - The authors suggest that schizophrenic patients unresponsive to other antipsychotic agents should be considered for a trial on loxapine. The loxapine dosage should be slowly titrated upward unless rapid tranquilization is indicated. Use of the liquid form of medication is recommended for initiation of routine loxapine therapy to assure compliance during titration. Loxapine has been reported to cause seizures in overdose, justifying careful screening of patients for high-dose loxapine therapy. Double-blind, placebo-controlled trials are needed to verify the superiority of loxapine over other antipsychotic agents.

UR - http://www.scopus.com/inward/record.url?scp=0021024766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021024766&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0021024766

VL - 19

SP - 600

EP - 603

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 4

ER -